Triclabendazole [CGP 23030] in the treatment of fascioliasis in man

ABSTRACT

Triclabendazole had been tested in veterinary medicine against fascioliasis. This study, using a form of triclabendazole, especially prepared for human use, aimed to assess tolerability and the clinical efficacy of that drug in the treatment of liver fluke infection in humans. 25 patients admitted to Tropical Medicine Research Institute. None less than 10 years of age, were diagnosed as positive cases for fascioliasis. The diagnosis was confirmed by repeated stool examination. All patients were examined and laboratory investigation included hematological studies, liver and kidney function tests, and abdominal ultrasonography were done before treatment and repeated at day 4 and 6, 30 and 60 post treatment. The cure rate was 100% after one week of therapy and 88% at 2 months post treatment. Triclabendazole [CGP] is tolerable, safe and effective in the treatment of cases with fascioliasis